Objective: To assess the diagnostic potential of imaging striatal monoaminergic terminal integrity with the vesicular monoamine transporter type 2 (VMAT2) radioligand 18 F 9-fluropropyl-(ϩ)-dihydrotetrabenazine ([ 18 F]AV-133) and positron emission tomography to distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD).
W
HILE ALZHEIMER DISease (AD) is the m o s t c o m m o n cause of dementia in elderly individuals, postmortem studies have found dementia with Lewy bodies (DLB) to account for 20% of cases. 1, 2 The pathological hallmark of DLB is the presence of ␣-synuclein-containing Lewy bodies within the neocortical, limbic, and paralimbic regions, [2] [3] [4] [5] [6] but as with idiopathic Parkinson disease (PD), there is also substantial loss of pigmented dopaminergic neurons in the substantia nigra and the consequent marked dopaminergic terminal loss in the striatum. 7, 8 The noninvasive evaluation of nigrostriatal dopaminergic integrity by positron emission tomography (PET) and single-photon emission computed tomography (SPECT) has provided useful clinical information for early and differential diagnosis of PD and for diagnosis of DLB from AD. The evaluation of nigrostriatal dopaminergic integrity was achieved by either assessing presynaptic dopamine synthesis or dopamine transporter (DAT) or vesicular monoamine transporter type 2 (VMAT2) densities. 9, 10 VMAT2 is the transporter responsible for uptake and storage of monoamines (dopamine, serotonin, and norepinephrine) into vesicles in monoamine-containing neurons. VMAT2 is mainly located on synaptic vesicles at the nerve terminals but also on dense core vesicles in nerve cell bodies and dendrites.
11 [ 11 C]-labeled dihydrotetrabenazine ([ 11 C]DTBZ) has been successfully used to quantify VMAT2 in PD as well as in the differential diagnosis between DLB and AD. 9, [12] [13] [14] [15] These PET studies have shown decreased [ 11 C]DTBZ binding to VMAT2 in the striatum of patients with PD and DLB. [16] [17] [18] [19] [20] A reduction of VMAT2 reflects the degeneration of nigrostriatal dopaminergic neurons and is less suscep-tible than DAT to compensatory changes occurring with the loss of dopaminergic neurons. 19, 21 A novel 18 F-labeled tetrabenazine derivative, 9-fluoropropyl-(ϩ)-dihydrotetrabenazine ([ 18 F]AV-133), that selectively binds with high affinity to VMAT2 has been developed to assess VMAT2 density in vivo with PET. [22] [23] [24] [
18 F]AV-133 PET has been shown to detect VMAT2 reductions in PD. 25 To assess the integrity of monoaminergic innervation as a differentiating feature in neurodegenerative diseases, a PET study was performed to compare [ 18 F]AV-133 binding in patients with DLB, PD, and AD as well as healthy controls (HCs). 26 All patients with DLB met consensus criteria for probable DLB 27 including progressive cognitive impairment with at least 2 of the 3 core features of (1) persistent visual hallucinations, (2) parkinsonian signs, and (3) fluctuation in cognitive performance. These criteria have a specificity of 90% for postmortem diagnosis of DLB. 28 Participants fulfilling clinical criteria for PD were recruited from Movement Disorders Clinics. All HCs performed within (Ͻ1.5 SD) the published norms for their age group on neuropsychological tests. Data from most of the HCs and patients with PD have appeared in a previous report. 25 All subjects underwent neurological and neuropsychological examinations. In regard to dopaminergic medication, 15 patients with PD were receiving carbidopa-levodopa; 2 were receiving selegiline; 2, levodopa and benserazide; and 1, pramipexole. In regard to dopaminergic medication among patients with DLB, 3 were receiving carbidopa-levodopa and 2, levodopa and benserazide. Six patients with DLB were receiving anticholinesterase medication. Seven patients with AD were receiving anticholinesterase medication, 1 was receiving risperidone, and 1 was taking Ginkgo biloba. Two patients, 1 with DLB and 1 with a diagnosis of AD, were taking no medication. The neurological evaluation of participants included the assessment of duration of illness, the HoehnYahr score, and the motor subscale (Section III) of the Unified Parkinson's Disease Rating Scale (UPDRS m ) both "off" (24 hours after the last medication dosage) and "on" parkinsonian medication for the PD cohort and "on" medication only for the patients with DLB. Treatment was resumed just before the PET scan. The neuropsychological evaluation included the Mini-Mental State Examination, Clinical Dementia Rating, the Hospital Anxiety and Depression Scale Fluctuating Assessment Scale, logical memory score, and verbal fluency score ( Table 1) . Clinical laterality of symptoms was assigned scores as previously described 25 to allow correlation analysis with the [ Thirteen participants (3 with PD, 2 HCs, 2 with DLB, and 6 with AD) underwent only the 120-to 140-minute static image acquisition. The sorted sinograms were reconstructed using a 3D row-action maximum likelihood algorithm. All subjects, except 1 patient with DLB , received a magnetic resonance imaging (MRI) scan for screening of other diseases. Seven patients with DLB, 5 patients with AD, and 5 patients with PD as well as 2 HCs had previous amyloid scans.
METHODS

PARTICIPANTS
IMAGE ANALYSIS
The dynamically acquired PET images of the 36 participants were converted into binding potential (BP) parametric images through Logan graphical analysis, with the PMOD software (version 3.0; PMOD Technologies, Zurich, Switzerland), using the primary visual cortex, a region relatively devoid of monoaminergic terminals, as input function. 16, 29 The static images of all participants acquired between 120 and 140 minutes were transformed into tissue ratio (R T ) parametric images using the primary visual cortex as the reference region. Parametric [ 16, 30 all comparisons and correlations were corrected for age effects. Receiver operating characteristic curve analysis was applied to assess the robustness of the different parameters to discriminate between the clinical groups. SPM5 was additionally used to evaluate intergroup [ 18 F]AV-133 R T differences on a voxelwise basis. Group comparisons between patients with DLB, AD, and PD and HCs were performed by voxel-by-voxel t tests, accepting only voxels surviving false discovery rate correction for the entire volume at a P value Ͻ.05 to avoid false-positive results.
STATISTICAL ANALYSIS
RESULTS
Demographic and clinical data are summarized in Table 1 scores in an off-medication state were significantly higher in patients with PD than patients with AD and HCs. The Hoehn-Yahr and UPDRS scores in the off-medication state were unavailable in 1 patient in the PD group and 1 patient in the DLB group, respectively. The Hoehn-Yahr and the UPDRS m scores in the onmedication state were significantly higher in patients with PD and DLB compared with HCs and patients with AD. There was no difference between the patients with PD and HCs in Clinical Dementia Rating, Fluctuating Assessment Scale score, logical memory score, and verbal fluency score.
In the 36 participants with dynamic PET scans, the degree of association between striatal BP and striatal R T values was explored. Correlation analysis showed very high association (r = 0. (Figure 2) . Similarly, as previously reported for PD, 25 in DLB the greatest [
18 F]AV-133 R T reduction was observed in the posterior putamen (−74%), followed by the anterior putamen (−65%) and the caudate nuclei (−51%) (Figure 2 ). In the posterior putamen, mean [ with effect sizes of 2.1, 2.9, and 3.4 for the caudate and anterior and posterior putamen, respectively.
While there were no significant differences in the asymmetry indices for the striatal regions between patients with DLB and PD, there was a significant correlation between [ 18 F]AV-133 asymmetry indices in the striatum and the clinical laterality scores in the PD group but not in the DLB group. No striatal asymmetries were detected in the HC and AD groups. The striatal anterior to posterior ratio was significantly higher in patients with DLB compared with HCs and patients with AD ( Table 2) .
Analysis of extrastriatal VMAT2 R T values showed no significant differences between HCs and the other groups. An apparent reduction in hippocampal and temporal [ In patients with DLB, there was a significant correlation between Hoehn-Yahr scores and the anterior putamen R T (r = −0.82; P = .02), but no significant correlations were observed between striatal R T and the UPDRS m score, nor with the bradykinesia or rigidity subscores. While there were no significant correlations between striatal [ Table 3 ). An area under the curve of 1.00 was also obtained if all the striatal regions were grouped together. Areas under the curve of 0.71 and 0.86 were obtained for the striatal asymmetry index and the striatal anterior to posterior ratio, respectively (Table 3) . Using a striatal [ 
COMMENT
One of the diagnostic problems faced by clinicians, due to the overlap of cognitive symptoms early in the disease course, is the differential diagnosis between patients who will develop AD vs those who will ultimately develop DLB. While the introduction of amyloid imaging has been extremely useful in the early detection of A␤ deposits in the brain, 6 it is not a useful tool in differentiating between AD and DLB as the majority of DLB cases also show extensive cortical A␤ deposition. 2, 3, 5, 6 Molecular imaging studies with fluorodeoxyglucose (FDG) have shown that occipital hypometabolism with parietal involvement [31] [32] [33] and preservation of metabolic activity in the posterior cingulate 34, 35 are the most distinctive features of DLB, with FDG having a 75% to 85% accuracy in the differential diagnosis of DLB from AD. 20, 35, 36 Imaging presynaptic dopamine terminals, a quantitative marker of extent of neuronal degeneration and remodeling, may improve the early and accurate diagnosis of patients with DLB and appears more accurate than FDG-PET. 20, 37, 38 This discovery has been translated into clinical practice in Europe where an iodine 123-labeled DAT SPECT ligand (DatScan; GE Healthcare, Buckinghamshire, England) is approved for diagnosis of PD and DLB. Unlike DAT, VMAT2 levels are less susceptible to compensatory regulation by pharmacological challenges, making VMAT2 a robust marker of monoaminergic terminal integrity. 13, 39, 40 Until recently, [ 11 C]DTBZ was the only available PET tracer for the noninvasive quantification of VMAT2 density in the brain. Unfortunately, the 20-minute radioactive decay half-life of 11 C limits the use of [
11 C]DTBZ to centers with an on-site cyclotron and expertise in 11 C radiochemistry, while the high cost of studies make it prohibitive for routine clinical use. To overcome these limitations, a VMAT2 tracer labeled with 18 F (T1/2 110 minutes) was developed 22, 24 and shown to be an excellent surrogate marker for the detection of nigrostriatal degeneration in PD. 25 The results presented here demonstrate the usefulness of assessing the integrity of the nigrostriatal pathways, either by visual inspection of images or semiquantitatively with 45 In a similar fashion, the present study demonstrated a 37% reduction of [
18 F]AV-133 binding in the anterior midbrain of patients with PD and DLB, consistent with previous reports of nigral VMAT2 reductions. 19 As pointed out in our report on patients with PD, the high correlation between clinical and [ 18 F]AV-133 asymmetry indices as well as the associations observed between the clinical subscores and striatal VMAT2 densities in PD are suggestive of disease severity. 25 While more accurate than [ 18 F]-DOPA, 18 [ 18 F]AV-133 R T might not be reflecting the true extent of nigrostriatal neurodegeneration, where compensatory mechanisms such as overproduction of dopamine and aberrant sprouting of ter- 46 precluding a true evaluation of the pathological process. Furthermore, the associations or lack thereof observed between the clinical scores and subscores in patients with DLB should be interpreted cautiously. The neurological assessments in this group were performed while "on" medication, and moreover, not all patients were receiving dopaminergic medication. Seven of the 9 patients with DLB also had a previous amyloid imaging scan. Interestingly, while there were no differences in either [
18 F]AV-133 R T values or motor or fluctuation scale scores, patients with DLB with high A␤ burden in the brain had a much shorter time from onset of symptoms to clinical diagnosis. While the very small number of subjects precludes drawing definitive conclusions, these results suggest that in addition to the reductions of dopaminergic nigrostriatal afferents, those patients with DLB with significant A␤ deposits in the brain have a shorter prodromal phase, in agreement with our previous reports 6 and with the proposed role of A␤ in DLB, where A␤ deposits result in greater aggregation and exacerbation ␣-synuclein-dependent neuronal injury. 47 There are some limitations in the present study. A severe limitation in the present study is that group classification was based on clinical evaluation, and although they fulfilled diagnostic criteria, postmortem confirmation was not available. Given the complexity and sometimes overlapping clinical features of AD and DLB, especially early in the disease course, neuropathological examination will be required not only to characterize the relationship between the integrity of monoaminergic innervation and the [
18 F]AV-133 PET signal, but also to ascertain if VMAT2 imaging with [
18 F]AV-133 is able to provide the diagnostic certainty required for the detection of nigrostriatal degeneration. Another weakness in the present study is that there were a limited number of patients examined. This study by its design cannot show that VMAT2 imaging has any advantage over clinical diagnosis. Prospective studies in at-risk persons, such as subjects with rapid eye movement sleep behavioral disorder, 48, 49 or patients with atypical presentations that compare initial clinical diagnosis and management with and without [ 18 F]AV-133 PET findings with long-term clinical or postmortem outcome are needed. Such studies have demonstrated the value of DAT imaging with SPECT for more accurate diagnosis than can be achieved from clinical assessment. 50 It is likely that VMAT2 imaging will have similar clinical benefits.
CONCLUSIONS
In conclusion, similar to what has been observed in PD, significant VMAT2 reductions were detected in the striatum and midbrain of patients with DLB with [
18 F]AV-133, while there were no VMAT2 alterations in patients with AD. These observations indicate that a 20-minute [
